The Annual Meeting of the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium brings together clinicians, researchers, and members of the NEALS Consortium to share the latest data and findings in the care of ALS, and discuss the hottest topics in neuromuscular medicine.
ALS Research on Genetic Testing and Counseling Provides Evidence-Based Consensus Guidelines for CliniciansNovember 12th 2022
Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.
Critical Takeaways, Learning Experiences From the Tofersen Trials in ALS: Timothy Miller, MD, PhDNovember 11th 2022
The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]
Role of Tofersen Among Other Previously Approved ALS Therapies: Timothy Miller, MD, PhDNovember 10th 2022
The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]
NurOwn Stromal Cell Therapy Continues to Show Positive Data in Less Severe ALSNovember 9th 2022
After removing participants at higher risk of reaching a floor effect of the ALSFRS-R, those treated with NurOwn demonstrated a higher rate of clinical response and less function lost across 28 weeks than placebo.
Understanding Tofersen’s Impact on SOD1 ALS, Neurofilament Light: Timothy Miller, MD, PhDNovember 9th 2022
The codirector of the ALS Center at Washington University School of Medicine in St. Louis discussed the long-term data of VALOR and its open-label extension assessing tofersen (Biogen) in SOD1 ALS. [WATCH TIME: 4 minutes]
Patient-Reported Outcomes Worsen as ALS Disease Progresses, Real-World Study ShowsNovember 4th 2022
On King’s staging systems, ALSAQ-5 scores increased from 24.6 at stage 1 to 62.1 at stage 4, whereas for Milano-Torino Staging systems, patients’ ALSAQ-5 scores increased from 43.2 at stage 0 to 80.7 at stage 3.
Palatability Strategies Show Promise for Addressing AMX0035 Taste Concerns Among Patients With ALSNovember 2nd 2022
As patients with ALS may have altered taste perception and have expressed that bitterness is associated with AMX0035 (Relyvrio; Amylyx) administration, a number of coping strategies have suggested a workaround to ensure treatment adherence and effectiveness.
The ALS MOTOR as a Beneficial and Accessible Tool for Virtually Tracking ALS ProgressionNovember 2nd 2022
Christina Fournier, MD, MSc, associate professor of neurology, Emory University, discussed her presentation at the 2022 NEALS Consortium using a telemedicine exam to track ALS progression.
SBT-272 Shows Neuroprotective Impacts in ALS Mouse Models of TDP-43 PathologyNovember 2nd 2022
SBT-272, an investigational small molecule in development for ALS and other neurological disease of mitochondrial dysfunction, resulted in improved membrane potential and axonal outgrowth of TDP-43 in vitro.